Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial
暂无分享,去创建一个
N. Karalus | D. Milne | Conroy A Wong | L. Jayaram | H. Hockey | W. Fergusson | T. Ashton | Tam Eaton | C. Tong | Christine M. Tuffery | P. Sexton | Louanne Storey | T. Eaton
[1] M. McGuckin,et al. The Bronchiectasis And Low-Dose Erythromycin Study (BLESS) , 2012, ATS 2012.
[2] S. Holland,et al. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. , 2011, Chest.
[3] H. Imaoka,et al. Azithromycin and the risk of cardiovascular death. , 2012, The New England journal of medicine.
[4] W. Boersma,et al. Long term azithromycin treatment: A randomised placebo-controlled trial in non-CF bronchiectasis; results from the BAT trial , 2011 .
[5] D. Rubinsztein,et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. , 2011, The Journal of clinical investigation.
[6] You-ning Liu,et al. Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. , 2011, The Journal of antimicrobial chemotherapy.
[7] J. Maurer. Trends and Burden of Bronchiectasis-Associated Hospitalizations in the United States, 1993-2006 , 2011 .
[8] J. DiNicolantonio,et al. Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.
[9] W. Boersma,et al. Immunomodulatory Effects of Macrolide Antibiotics – Part 2: Advantages and Disadvantages of Long-Term, Low-Dose Macrolide Therapy , 2010, Respiration.
[10] R. Hubbard,et al. Trends in bronchiectasis mortality in England and Wales. , 2010, Respiratory medicine.
[11] B. Rubin,et al. Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications , 2010, Clinical Microbiology Reviews.
[12] D Bilton,et al. British Thoracic Society guideline for non-CF bronchiectasis , 2010, Thorax.
[13] C. Goss,et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. , 2010, JAMA.
[14] D. Hansell,et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival , 2009, European Respiratory Journal.
[15] E. Chilvers,et al. Azithromycin therapy for neutrophilic airways disease: myth or magic? , 2009, Thorax.
[16] A. Chang,et al. Exacerbations in cystic fibrosis: 4 · Non-cystic fibrosis bronchiectasis , 2008, Thorax.
[17] T. Ferkol,et al. Airway inflammation in cystic fibrosis. , 2008, Chest.
[18] J. Soriano,et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. , 2007, Chest.
[19] H. Goossens,et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study , 2007, The Lancet.
[20] H. Goossens,et al. Eff ect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers : a randomised , double-blind , placebo-controlled study , 2007 .
[21] P. King,et al. Characterisation of the onset and presenting clinical features of adult bronchiectasis. , 2006, Respiratory medicine.
[22] J. Jais,et al. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial , 2006, Thorax.
[23] N. Kiper,et al. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis 1 , 2006, Journal of clinical pharmacy and therapeutics.
[24] R. Pauwels,et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD , 2005, European Respiratory Journal.
[25] M. Martínez-García,et al. Quality-of-life determinants in patients with clinically stable bronchiectasis. , 2005, Chest.
[26] M. P. van der Linden,et al. Antimicrobial Susceptibility of Streptococcus pneumoniae in Eight European Countries from 2001 to 2003 , 2005, Antimicrobial Agents and Chemotherapy.
[27] L. Saiman,et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. , 2003, JAMA.
[28] J. Wedzicha,et al. COPD exacerbations: definitions and classifications , 2003, European Respiratory Journal.
[29] M. Rosenthal,et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial , 2002, The Lancet.
[30] R. Djukanović,et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation , 2002, European Respiratory Journal.
[31] S. Bell,et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial , 2002, Thorax.
[32] W. Chaicumpa,et al. Blinded, placebo-controlled trial of antiparasitic drugs for trichinosis myositis. , 2000, The Journal of infectious diseases.
[33] Wai Lam,et al. A pilot study of low-dose erythromycin in bronchiectasis. , 1999, The European respiratory journal.
[34] A. O'donnell,et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. , 1998, Chest.
[35] P. Jones,et al. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. , 1997, American journal of respiratory and critical care medicine.
[36] K. Sung,et al. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. , 1997, The European respiratory journal.
[37] D. Naidich,et al. Bronchiectasis: CT/clinical correlations. , 1995, Seminars in ultrasound, CT, and MR.